Public Company News

The intrigue around Legend Mining’s Fraser Range project is building as the company prepares to undertake two Down Hole Survey’s in search of the source of two strong magnetic conductors. The company believes it may have just missed the conductors with its drill holes and the downhole survey is capable of detecting conductors up to 100m off hole. 

In a supreme show of faith in ASX listed Analytica’s urinary incontinence medical device technology, its Chairman Dr Michael Monsour has agreed to take a $1m placement at a price nearly 18 percent higher than that offered to the general shareholder base and a new cornerstone investor who has also committed to a $500k placement. 

There’s an old saying in the exploration business - “If you want to hunt for elephants you need to go to elephant country." That message certainly hasn’t been lost on Sipa Resources who have just muscled into well known elephant country in the Pilbara that hosts the 10m ounce Telfer Gold mine and the 30 000 tonne a year Nifty Copper mine. Sipa will spend $3m to earn 80%.

A major part of Stargroup’s plan is about to come to fruition with the appointment of 20 agents nationwide who will resell their EFTPOS and PAYWAVE offering to businesses around the country.They are aiming to place 30 EFTPOS terminals a month into businesses up until July and 100 a month thereafter as their network of agents grows to over 100 by midyear. 

Blackham Resources haven’t wasted any time in putting their recent $20m capital raise to good use with the key refurbishment contract at the old Wiluna Gold plant now approved for signing. Blackham’s DFS predicts the project will bank $234m over 7 years which is not bad considering they only dished out around $6m to buy it and $32m to refurbish the plant. 

Burleson Energy acquisition Sky and Space Global have pre-sold 100% of the telecommunications bandwidth from their first constellation of “nano-satellites” to be launched in 2017. The company says that just 100 units should provide revenues of between $300m and $500m per annum and produce up to 1 000 000 000  minutes of voice, messaging and data air time a year.

Blackham Resources has added another 40 000 ounces of gold to its resource and another $20m to its bank account after a successful drilling campaign followed by an equally successful oversubscribed capital raise. The headline result from the campaign was 11.5m @ 5.08 grams per tonne gold which included a 7m intersection grading 7.01 grams per tonne gold.

Hammer Resources and heavyweight partner Newmont are currently processing and modelling geophysical data gleaned from the first round of field programs at Hammer’s Mt Isa project. Hammer are also focusing on their own 100% owned tenements including the Scalper prospect that retunred a result of 23 metres at 1.1% Copper and 0.27g/t gold.

Respected Florida based US research house Redchip, has re-rated ASX listed cancer drug hopeful Pharmaust at 35c a share, almost triple its current share price. The total Net Present Value calculated by Redchip for Pharmaust out to 2030 is $56.5m, considerably higher than Pharmaust’s current market cap that hovers between $10m and around $12m.

West Perth based Drake Resources has made the popular leap from mining to technology with the acquisition of Israeli based cyber security firm Genome Technologies that boasts a unique proprietary algorithm that “profiles” client company employees in order to assess their cyber security risk. The deal is worth around $11m and Drake says the cyber security market will grow to $177b in 5 years.

ASX listed Philippines high grade gold explorer Red Mountain Mining look set to bank $2.65m in the next few weeks after a strong showing in their recent rights issue and the listing of their strategic financing partner on the London Stock Exchange. 

Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer. The trials, which will analyse the effect of Monepantel on patient’s tumours are designed to provide short term feedback on the efficacy of the drug.